Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.855 GBX | +6.00% | +30.18% | -72.31% |
Apr. 30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
Apr. 30 | Transcript : Shield Therapeutics plc, 2023 Earnings Call, Apr 30, 2024 |
Sales 2023 * | 12.36M 15.5M | Sales 2024 * | 36.29M 45.51M | Capitalization | 13.69M 17.16M |
---|---|---|---|---|---|
Net income 2023 * | -27M -33.86M | Net income 2024 * | -10M -12.54M | EV / Sales 2023 * | 1.33 x |
Net Debt 2023 * | 2.81M 3.53M | Net Debt 2024 * | 16.73M 20.98M | EV / Sales 2024 * | 0.84 x |
P/E ratio 2023 * |
-0.45
x | P/E ratio 2024 * |
-1.01
x | Employees | 27 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 43.82% |
Latest transcript on Shield Therapeutics plc
1 day | +29.63% | ||
1 week | +22.81% | ||
Current month | -13.58% | ||
1 month | -12.50% | ||
3 months | -72.66% | ||
6 months | -72.22% | ||
Current year | -73.88% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 18-07-25 | |
Director/Board Member | 66 | 16-01-31 | |
Director/Board Member | 57 | 21-05-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 1.855 | +6.00% | 2 684 547 |
24-05-01 | 1.75 | +29.63% | 19,413,980 |
24-04-30 | 1.35 | 0.00% | 13,190,020 |
24-04-29 | 1.35 | 0.00% | 5,942,486 |
24-04-26 | 1.35 | +10.20% | 8,345,835 |
Delayed Quote London S.E., May 01, 2024 at 11:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-73.88% | 17.09M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- STX Stock